Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2011 (2011), Article ID 516219, 11 pages
http://dx.doi.org/10.1155/2011/516219
Research Article

Newborn Mice Vaccination with BCG.HIVA222 + MVA.HIVA Enhances HIV-1-Specific Immune Responses: Influence of Age and Immunization Routes

1AIDS Research Unit, Hospital Clínic/IDIBAPS-HIVACAT, University of Barcelona, Calle Villarroel 170, 08036 Barcelona, Spain
2MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford University and The John Radcliffe, Oxford OX3 9DS, UK
3Unitat Tuberculosi Experimental, Institut “Germans Trias i Pujol”, Carretera del Canyet S/N, Badalona 08916, Barcelona, Spain

Received 15 September 2010; Accepted 1 February 2011

Academic Editor: Eiji Matsuura

Copyright © 2011 Narcís Saubi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Children on the Brink, New York, NY, USA, 4th edition, 2004, A Population, Health and Nutrition Information Project under USAID contract no. HRN-C-00-00-0004-00. The Joint United Nations Programme on HIV/AIDS (UNAIDS), the United Nations Children's Fund (UNICEF), and the United States Agency for International Development (USAID). United Nations Children's Fund, 3 United Nations Plaza.
  2. AIDS Epidemic Update, Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS, Geneva, Switzerland, 2010.
  3. U. D. Ranganathan, M. H. Larsen, J. Kim, S. A. Porcelli, W. R. Jacobs Jr., and G. J. Fennelly, “Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice,” Vaccine, vol. 28, no. 1, pp. 152–161, 2010. View at Google Scholar
  4. I. P. Nascimento, W. O. Dias, W. Quintilio et al., “Neonatal immunization with a single dose of recombinant BCG expressing subunit S1 from pertussis toxin induces complete protection against Bordetella pertussis intracerebral challenge,” Microbes and Infection, vol. 10, no. 2, pp. 198–202, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Joseph, N. Saubi, E. Pezzat, and J. M. Gatell, “Progress towards an HIV vaccine based on recombinant Bacillus Calmette-Guérin: failures and challenges,” Expert Review of Vaccines, vol. 5, no. 6, pp. 827–838, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Dennehy and A. L. Williamson, “Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines,” Vaccine, vol. 23, no. 10, pp. 1209–1224, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Lotte, O. Wasz-Höckert, N. Poisson, N. Dumitrescu, M. Verron, and E. Couvet, “BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics,” Advances in Tuberculosis Research, vol. 21, pp. 107–193, 1984. View at Google Scholar · View at Scopus
  8. M. Gheorghiu, P. H. Lagrange, and C. Fillastre, “The stability and immunogenocity of a dispersed-grown freeze-dried Pasteur BCG vaccine,” Journal of Biological Standardization, vol. 16, no. 1, pp. 15–26, 1988. View at Google Scholar · View at Scopus
  9. M. Kawada, T. Tsukamoto, H. Yamamoto et al., “Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial,” Journal of Virology, vol. 82, no. 20, pp. 10199–10206, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Matano, M. Kobayashi, H. Igarashi et al., “Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial,” Journal of Experimental Medicine, vol. 199, no. 12, pp. 1709–1718, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. J. E. Schmitz, M. J. Kuroda, S. Santra et al., “Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes,” Science, vol. 283, no. 5403, pp. 857–860, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. N. L. Letvin, “Strategies for an HIV vaccine,” Journal of Clinical Investigation, vol. 110, no. 1, pp. 15–20, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Hanke and A. J. McMichael, “Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya,” Nature Medicine, vol. 6, no. 9, pp. 951–955, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. E. J. Im, N. Saubi, G. Virgili et al., “Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding,” Journal of Virology, vol. 81, no. 17, pp. 9408–9418, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Joseph, R. Ferndez-Lloris, E. Pezzat et al., “Molecular characterization of heterologous HIV-1gp120 gene expression disruption in mycobacterium bovis BCG host strain: a critical issue for engineering Mycobacterial based-vaccine vectors,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 357370, 10 pages, 2010. View at Publisher · View at Google Scholar
  16. M. C. Raviglione, D. E. Snider Jr., and A. Kochi, “Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic,” Journal of the American Medical Association, vol. 273, no. 3, pp. 220–226, 1995. View at Google Scholar · View at Scopus
  17. D. Young and C. Dye, “The development and impact of tuberculosis vaccines,” Cell, vol. 124, no. 4, pp. 683–687, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. World Health Organization, “Outbreak news,” The Weekly Epidemiological Record, vol. 76, pp. 33–40, 2001. View at Google Scholar
  19. M. A. Horwitz and G. Harth, “A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis,” Infection and Immunity, vol. 71, no. 4, pp. 1672–1679, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. G. A. Colditz, T. F. Brewer, C. S. Berkey et al., “Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature,” Journal of the American Medical Association, vol. 271, no. 9, pp. 698–702, 1994. View at Publisher · View at Google Scholar · View at Scopus
  21. I. F. Hermans, J. D. Silk, J. Yang et al., “The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo,” Journal of Immunological Methods, vol. 285, no. 1, pp. 25–40, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Alter, J. M. Malenfant, and M. Altfeld, “CD107a as a functional marker for the identification of natural killer cell activity,” Journal of Immunological Methods, vol. 294, no. 1-2, pp. 15–22, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. S. André, B. Seed, J. Eberle, W. Schraut, A. Bültmann, and J. Haas, “Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage,” Journal of Virology, vol. 72, no. 2, pp. 1497–1503, 1998. View at Google Scholar · View at Scopus
  24. S. G. E. Andersson and P. M. Sharp, “Codon usage in the Mycobacterium tuberculosis complex,” Microbiology, vol. 142, no. 4, pp. 915–925, 1996. View at Google Scholar · View at Scopus
  25. A. B. de Miranda, F. Alvarez-Valin, K. Jabbari, W. M. Degrave, and G. Bernardi, “Gene expression, amino acid conservation, and hydrophobicity are the main factors shaping codon preferences in Mycobacterium tuberculosis and Mycobacterium leprae,” Journal of Molecular Evolution, vol. 50, no. 1, pp. 45–55, 2000. View at Google Scholar · View at Scopus
  26. C. K. Stover, G. P. Bansal, M. S. Hanson et al., “Protective immunity elicited by recombinant bacille Calmette-Guérin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine,” Journal of Experimental Medicine, vol. 178, no. 1, pp. 197–209, 1993. View at Google Scholar · View at Scopus
  27. H. Takahashi, J. Cohen, A. Hosmalin et al., “An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility comples molecule-restricted murine cytotoxic T lymphocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 9, pp. 3105–3109, 1988. View at Google Scholar · View at Scopus
  28. M. S. Pavelka Jr. and W. R. Jacobs, “Comparison of the construction of unmarked deletion mutations in Mycobacterium smegmatis, Mycobacterium bovis bacillus Calmette-Guérin, and Mycobacterium tuberculosis H37RV by allelic exchange,” Journal of Bacteriology, vol. 181, no. 16, pp. 4780–4789, 1999. View at Google Scholar · View at Scopus
  29. Section 5.2.6, European Pharmacopoeia, Published by the Council of Europe, 7th edition, 2010.
  30. M. J. Cayabyab, A. H. Hovav, T. Hsu et al., “Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 env,” Journal of Virology, vol. 80, no. 4, pp. 1645–1652, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Aldovini and R. A. Young, “Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines,” Nature, vol. 351, no. 6326, pp. 479–482, 1991. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Honda, K. Matsuo, T. Nakasone et al., “Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 23, pp. 10693–10697, 1995. View at Publisher · View at Google Scholar · View at Scopus
  33. C. K. Stover, V. F. de La Cruz, T. R. Fuerst et al., “New use of BCT for recombinant vaccines,” Nature, vol. 351, no. 6326, pp. 456–460, 1991. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Yasutomi, S. Koenig, S. S. Haun et al., “Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys,” Journal of Immunology, vol. 150, no. 7, pp. 3101–3107, 1993. View at Google Scholar · View at Scopus
  35. Y. Ami, Y. Izumi, K. Matsuo et al., “Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity,” Journal of Virology, vol. 79, no. 20, pp. 12871–12879, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. M. J. Cayabyab, B. Korioth-Schmitz, Y. Sun et al., “Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses,” Journal of Virology, vol. 83, no. 11, pp. 5505–5513, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. H. McShane, A. A. Pathan, C. R. Sander et al., “Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans,” Nature Medicine, vol. 10, no. 11, pp. 1240–1244, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. H. M. Vordermeier, B. Villarreal-Ramos, P. J. Cockle et al., “Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis,” Infection and Immunity, vol. 77, no. 8, pp. 3364–3373, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. A. H. Hovav, M. W. Panas, C. E. Osuna, M. J. Cayabyab, P. Autissier, and N. L. Letvin, “The impact of a boosting immunogen on the differentiation of secondary memory CD8+ T cells,” Journal of Virology, vol. 81, no. 23, pp. 12793–12802, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Lagranderie, N. Winter, A. M. Balazuc, B. Gicquel, and M. Gheorghiu, “A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, EnV, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes,” AIDS Research and Human Retroviruses, vol. 14, no. 18, pp. 1625–1633, 1998. View at Google Scholar · View at Scopus
  41. M. Kawahara, K. Matsuo, T. Nakasone et al., “Combined intrarectal/intradermal inoculation of recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces enhanced immune responses against the inserted HIV-1 V3 antigen,” Vaccine, vol. 21, no. 3-4, pp. 158–166, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Promkhatkaew, K. Matsuo, N. Pinyosukhee et al., “Prime-boost vaccination using recombinant mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-I CRF01-AE gag in mice: influence of immunization routes,” Southeast Asian Journal of Tropical Medicine and Public Health, vol. 40, no. 2, pp. 273–281, 2009. View at Google Scholar · View at Scopus
  43. U. D. K. Ranganathan, M. H. Larsen, J. Kim, S. A. Porcelli, W. R. Jacobs Jr., and G. J. Fennelly, “Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice,” Vaccine, vol. 28, no. 1, pp. 152–161, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Rosario, J. Fulkerson, S. Soneji et al., “Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus ankara vaccines in neonate rhesus macaques,” Journal of Virology, vol. 84, no. 15, pp. 7815–7821, 2010. View at Publisher · View at Google Scholar
  45. M. O. C. Ota, J. Vekemans, S. E. Schlegel-Haueter et al., “Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination,” Journal of Immunology, vol. 168, no. 2, pp. 919–925, 2002. View at Google Scholar · View at Scopus
  46. C. Barrios, P. Brawand, M. Berney, C. Brandt, P.-H. Lambert, and C.-A. Siegrist, “Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting,” European Journal of Immunology, vol. 26, no. 7, pp. 1489–1496, 1996. View at Publisher · View at Google Scholar
  47. A. Marchant, T. Goetghebuer, M. O. Ota et al., “Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guérin vaccination,” Journal of Immunology, vol. 163, no. 4, pp. 2249–2255, 1999. View at Google Scholar · View at Scopus
  48. J. Vekemans, A. Amedei, M. O. Ota et al., “Neonatal bacillus Calmette-Guérin vaccination induces adult-like IFN-γ production by CD4+ T lymphocytes,” European Journal of Immunology, vol. 31, no. 5, pp. 1531–1535, 2001. View at Publisher · View at Google Scholar · View at Scopus